|
1
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rawla P, Sunkara T and Barsouk A:
Epidemiology of colorectal cancer: Incidence, mortality, survival,
and risk factors. Prz Gastroenterol. 14:89–103. 2019.PubMed/NCBI
|
|
3
|
Kannarkatt J, Joseph J, Kurniali PC,
Al-Janadi A and Hrinczenko B: Adjuvant chemotherapy for stage II
colon cancer: A clinical dilemma. J Oncol Pract. 13:233–241. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Goldberg RM, Rothenberg ML, Van Cutsem E,
Benson AB III, Blanke CD, Diasio RB, Grothey A, Lenz HJ, Meropol
NJ, Ramanathan RK, et al: The continuum of care: A paradigm for the
management of metastatic colorectal cancer. Oncologist. 12:38–50.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Burgers K, Moore C and Bednash L: Care of
the colorectal cancer survivor. Am Fam Physician. 97:331–336.
2018.PubMed/NCBI
|
|
6
|
Muhammad S, Kaur K, Huang R, Zhang Q, Kaur
P, Yazdani HO, Bilal MU, Zheng J, Zheng L and Wang XS: MicroRNAs in
colorectal cancer: Role in metastasis and clinical perspectives.
World J Gastroenterol. 20:17011–17019. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stewart CL, Warner S, Ito K, Raoof M, Wu
GX, Kessler J, Kim JY and Fong Y: Cytoreduction for colorectal
metastases: Liver, lung, peritoneum, lymph nodes, bone, brain. When
does it palliate, prolong survival, and potentially cure? Curr
Probl Surg. 55:330–379. 2018.PubMed/NCBI
|
|
8
|
Shibue T and Robert A: Weinberg. EMT CSCs
and drug resistance: The mechanistic link and clinical
implications. Nat Rev Clin Oncol. 14:611–629. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Garza-Trevino EN, Said-Fernandez SL and
Martinez-Rodriguez HG: Understanding the colon cancer stem cells
and perspectives on treatment. Cancer Cell Int. 15:22015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bezuidenhout N and Shoshan M: A shifty
target: Tumor-initiating cells and their metabolism. Int J Mol Sci.
20:53702019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Garza Treviño EN, González PD, Valencia
Salgado CI and Martinez Garza A: Effects of pericytes and colon
cancer stem cells in the tumor microenvironment. Cancer Cell Int.
19:1732019. View Article : Google Scholar
|
|
12
|
Prasetyanti PR and Medema JP: Intra-tumor
heterogeneity from a cancer stem cell perspective. Mol Cancer.
16:412017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Singh M, Yelle N, Venugopal C and Singh
SK: EMT: Mechanisms and therapeutic implications. Pharmacol Ther.
182:80–94. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim WT and Ryu CJ: Cancer stem cell
surface markers on normal stem cells. BMB Rep. 50:285–298. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sahlberg SH, Spiegelberg D, Glimelius B,
Stenerlöw B and Nestor M: Evaluation of cancer stem cell markers
CD133, CD44, CD24: Association with AKT isoforms and radiation
resistance in colon cancer cells. PLoS One. 9:e946212014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Han L, Shi S, Gong T, Zhang Z and Sun X:
Cancer stem cells: Therapeutic implications and perspectives in
cancer therapy. Acta Pharm Sin B. 3:65–75. 2013. View Article : Google Scholar
|
|
17
|
Bao B, Ahmad A, Azmi AS, Ali S and Sarkar
FH: Overview of cancer stem cells (CSCS) and mechanisms of their
regulation: Implications for cancer therapy. Curr Protoc Pharmacol.
14:1–18. 2013.
|
|
18
|
Turdo A, Veschi V, Gaggianesi M, Chinnici
A, Bianca P, Todaro M and Stassi G: Meeting the challenge of
targeting cancer stem cells. Front Cell Dev Biol. 7:162019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Markowska A, Sajdak S, Markowska J and
Huczyński A: Angiogenesis and cancer stem cells: New perspectives
on therapy of ovarian cancer. Eur J Med Chem. 142:87–94. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hodgkinson N, Kruger CA and Abrahamse H:
Targeted photodynamic therapy as potential treatment modality for
the eradication of colon cancer and colon cancer stem cells. Tumor
Biol. 39:10104283177346912017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gonzalez-Villarreal CA, Quiroz-Reyes AG,
Islas JF and Garza-Treviño EN: Colorectal cancer stem cells in the
progression to liver metastasis. Front Oncol. 10:15112020.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Spano JP, Milano G, Vignot S and Khayat D:
Potential predictive markers of response to EGFR-targeted therapies
in colorectal cancer. Crit Rev Oncol Hematol. 66:21–30. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Deschoolmeester V, Baay M, Specenier P,
Lardon F and Vermorken JB: A review of the most promising
biomarkers in colorectal cancer: One step closer to targeted
therapy. Oncologist. 15:699–731. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Moradi Marjaneh R, Khazaei M, Ferns GA,
Avan A and Aghaee-Bakhtiari SH: MicroRNAs as potential therapeutic
targets to predict responses to oxaliplatin in colorectal cancer:
From basic evidence to therapeutic implication. IUBMB Life.
71:1428–1441. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rodrigues D, Longatto-Filho A and Martins
SF: Predictive biomarkers in colorectal cancer: From the single
therapeutic target to a plethora of options. Biomed Res Int.
2016:68960242016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xie YH, Chen YX and Fang JY: Comprehensive
review of targeted therapy for colorectal cancer. Signal Transduct
Target Ther. 5:222020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Péus D, Newcomb N and Hofer S: Appraisal
of the Karnofsky Performance Status and proposal of a simple
algorithmic system for its evaluation. BMC Med Inform Decis Mak.
13:722013. View Article : Google Scholar
|
|
28
|
Prager BC, Xie Q, Bao S and Rich JN:
Cancer stem cells: The architects of the tumor ecosystem. Cell Stem
Cell. 24:41–53. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cammareri P, Lombardo Y, Francipane MG,
Bonventre S, Todaro M and Stassi G: Isolation and culture of colon
cancer stem cells. Methods Cell Biol. 86:311–324. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang J, Hu S and Li Y: KRT18 is
correlated with the malignant status and acts as an oncogene in
colorectal cancer. Biosci Rep. 39:BSR201908842019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang H, Gong P, Chen T, Gao S, Wu Z, Wang
X, Li J, Marjani SL, Costa J, Weissman SM, et al: Colorectal cancer
stem cell states uncovered by simultaneous single-cell analysis of
transcriptome and telomeres. Adv Sci (Weinh). 8:20043202021.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jahanafrooz Z, Mosafer J, Akbari M,
Hashemzaei M, Mokhtarzadeh A and Baradaran B: Colon cancer therapy
by focusing on colon cancer stem cells and their tumor
microenvironment. J Cell Physiol. 235:4153–4166. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hammond WA, Swaika A and Mody K:
Pharmacologic resistance in colorectal cancer: A review. Ther Adv
Med Oncol. 8:57–84. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Blom K, Nygren P, Larsson R and Andersson
CR: Predictive value of ex vivo chemosensitivity assays for
individualized cancer chemotherapy: A meta-analysis. SLAS Technol.
22:306–314. 2017.PubMed/NCBI
|
|
35
|
Kwon HY, Kim IK, Kang J, Sohn SK and Lee
KY: In vitro adenosine triphosphate-based chemotherapy response
assay as a predictor of clinical response to fluorouracil-based
adjuvant chemotherapy in stage II colorectal cancer. Cancer Res
Treat. 48:970–977. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Garza-Trevino EN, Rodriguez-Gonzalez MS,
Gonzalez PD, Alonso-Cruz YG, Alonso-Cruz YG, Soto-Dominguez A,
Guerrero JFG, Castro-Govea Y, Sanchez EM, Fernandez SS and
Martinez-Rodriguez HG: Remarkably higher efficacy and a wider
safety window for nonfrontline over first-line drug combinations in
the adenocarcinoma Colo 320DM cell line. J BUON. 22:1115–1121.
2017.PubMed/NCBI
|
|
37
|
Casbas-Hernandez P, Sun X, Roman-Perez E,
D'Arcy MD, Sandhu R, Hishida A, McNaughton KK, Yang XR, Makowski L,
Sherman ME, et al: Tumor intrinsic subtype is reflected in
cancer-adjacent tissue. Cancer Epidemiol Biomarkers Prev.
24:406–414. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hoesl C, Zanuttigh E, Fröhlich T,
Philippou-Massier J, Krebs S, Blum H and Dahlhoff M: The secretome
of skin cancer cells activates the mTOR/MYC pathway in healthy
keratinocytes and induces tumorigenic properties. Biochim Biophys
Acta Mol Cell Res. 1867:1187172020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Trevino V, Tadesse MG, Vannucci M,
Al-Shahrour F, Antczak P, Durant S, Bikfalvi A, Dopazo J, Campbell
MJ and Falciani F: Analysis of normal-tumour tissue interaction in
tumours: Prediction of prostate cancer features from the molecular
profile of adjacent normal cells. PLoS One. 6:e164922011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Colacino JA, Azizi E, Brooks MD, Harouaka
R, Fouladdel S, McDermott SP, Lee M, Hill D, Madden J, Boerner J,
et al: Heterogeneity of human breast stem and progenitor cells as
revealed by transcriptional profiling. Stem Cell Reports.
10:1596–1609. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Michaelis M, Wass MN and Cinatl J:
Drug-adapted cancer cell lines as preclinical models of acquired
resistance. Cancer Drug Resist. 2:447–456. 2019.
|
|
42
|
Izumi D, Ishimoto T, Sakamoto Y, Miyamoto
Y and Baba H: Molecular insights into colorectal cancer stem cell
regulation by environmental factors. J Cancer Metastasis Treat.
1:156–162. 2015. View Article : Google Scholar
|
|
43
|
Bakker WJ, Harris IS and Mak TW: FOXO3a is
activated in response to hypoxic stress and inhibits HIF1-induced
apoptosis via regulation of CITED2. Mol Cell. 28:941–953. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lähdeniemi IAK, Misiorek JO, Antila CJM,
Landor SKJ, Stenvall CGA, Fortelius LE, Bergström LK, Sahlgren C
and Toivola DM: Keratins regulate colonic epithelial cell
differentiation through the Notch1 signalling pathway. Cell Death
Differ. 24:984–996. 2017. View Article : Google Scholar
|
|
45
|
Danilkovitch-Miagkova A and Zbar B:
Dysregulation of Met receptor tyrosine kinase activity in invasive
tumors. J Clin Invest. 109:863–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rosario SR, Long MD, Affronti HC, Rowsam
AM, Eng KH and Smiraglia DJ: Pan-cancer analysis of transcriptional
metabolic dysregulation using the cancer genome atlas. Nat Commun.
9:53302018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jin N, Bi A, Lan X, Xu J, Wang X, Liu Y,
Wang T, Tang S, Zeng H, Chen Z, et al: Identification of metabolic
vulnerabilities of receptor tyrosine kinases-driven cancer. Nat
Commun. 10:27012019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Nguyeni TN, Nguyen HQ and Le DH: Unveiling
prognostics biomarkers of tyrosine metabolism reprogramming in
liver cancer by cross-platform gene expression analyses. PLoS One.
15:e02292762020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wu Z, Liu H, Sun W, Du Y, He W, Guo S,
Chen L, Zhao Z, Wang P, Liang H and Deng J: RNF180 mediates STAT3
activity by regulating the expression of RhoC via the proteasomal
pathway in gastric cancer cells. Cell Death Dis. 11:8812020.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wei F, Ba S, Jin M, Ci R, Wang X, Fusheng
E and Long Z: RNF180 inhibits proliferation and promotes apoptosis
of colorectal cancer through ubiquitination of WISP1. Front Cell
Dev Biol. 8:6234552021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Feng Y, Dai X, Li X, Wang H, Liu J, Zhang
J, Du Y and Xia L: EGF signalling pathway regulates colon cancer
stem cell proliferation and apoptosis. Cell Prolif. 45:413–419.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Yin S, Song M, Zhao R, Liu X, Kang WK, Lee
JM, Kim YE, Zhang C, Shim JH, Liu K, et al: Xanthohumol inhibits
the growth of keratin 18-overexpressed esophageal squamous cell
carcinoma in vitro and in vivo. Front Cell Dev Biol. 8:3662020.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Virag P, Fischer-Fodor E, Perde-Schrepler
M, Brie I, Tatomir C, Balacescu L, Berindan-Neagoe I, Victor B and
Balacescu O: Oxaliplatin induces different cellular and molecular
chemoresistance patterns in colorectal cancer cell lines of
identical origins. BMC Genomics. 14:4802013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Francipane MG, Bulanin D and Lagasse E:
Establishment and characterization of 5-fluorouracil-resistant
human colorectal cancer stem-like cells: Tumor dynamics under
selection pressure. Int J Mol Sci. 20:18172019. View Article : Google Scholar : PubMed/NCBI
|
